Key facts
- This page summarizes Keith S. Manchester's Form 4 filing for Arbutus Biopharma Corp (ABUS).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Aug 2024, 16:07.
Keith S. Manchester - 14 Aug 2024 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)
- Reporting relationship
- Director
- Issuer ticker
- ABUS
- Reported as of
- 14 Aug 2024
- Net transaction value
- -$1,885
- SEC form
- 4
- Accepted by SEC
- 16 Aug 2024, 16:07:41 UTC
- Prior SEC filing
- 24 May 2024
- Next SEC filing
- 12 Sep 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ David C. Hastings as attorney-in-fact for Keith S. Manchester
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Keith S. Manchester filed Form 4 for Arbutus Biopharma Corp (ABUS) on 16 Aug 2024.
Change
- Previous filing in this sequence was filed on 24 May 2024.
- Current net transaction value: -$1,885.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABUS
transaction
Common Shares
Options Exercise
- Transaction value
- $30,752
- Shares
- +54,915
- Change %
- Price
- $0.5600*
- Shares after
- 54,915
- Date
- 14 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
ABUS
transaction
Common Shares
Sale
- Transaction value
- $32,637
- Shares
- -8,846
- Change %
- -16%
- Price
- $3.69
- Shares after
- 46,069
- Date
- 14 Aug 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABUS
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -54,915
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 14 Aug 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 54,915
- Exercise price
- $0.5600
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Cashless exercise and hold transaction in director stock options due to expire on November 13, 2024, ten years after such options were granted, including the sale of 8,846 of the underlying shares to pay the exercise price. None of the net 46,069 shares were sold.
Footnote F2
This is a director stock option grant that is fully vested.